| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Outperform rating and announc...
BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $115 price target.
RBC Capital analyst Brian Abrahams initiates coverage on Apogee Therapeutics (NASDAQ: APGE) with a Outperform rating and ann...
Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with pote...